Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- On August 19, 2024, Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 1,728 shares of common stock.
- The sale was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $8.286, with individual transactions ranging from $8.27 to $8.30.
- Following the transaction, Burnett directly owns 194,859 shares of Arcutis Biotherapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't indicate any significant positive or negative sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock sale transaction |
| 08/21/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.